Nucleic Acids Research, 2002, Vol. 30, No. 2 559-568
© 2002 Oxford University Press
Allosteric inhibitors of telomerase: oligonucleotide N3'
P5' phosphoramidates
Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA
Telomerase is a ribonucleoprotein responsible for maintaining telomeres in nearly all eukaryotic cells. The enzyme is able to utilize a short segment of its RNA subunit as the template for the reverse transcription of d(TTAGGG) repeats onto the ends of human chromosomes. Transfection with telomerase was shown to confer immortality on several types of human cells. Moreover, telomerase activation appears to be one of the key events required for malignant transformation of normal cells. Inhibition of telomerase activity in transformed cells results in the cessation of cell proliferation in cultures and provides the rationale for the selection of telomerase as a target for anticancer therapy. Using oligonucleotide N3'
P5' phosphoramidates (NPs) we have identified a region of the human telomerase RNA subunit (hTR) 
100 nt downstream from the template region whose structural integrity appears crucial for telomerase enzymatic activity. The oligonucleotides targeted to this segment of hTR are potent and specific inhibitors of telomerase activity in biochemical assays. Mutant telomerase, in which 3 nt of hTR were not complementary to a 15 nt NP, was found to be refractory to inhibition by that oligonucleotide. We also demonstrated that the binding of NP, oligonucleotides to this hTR allosteric site results in a marked decrease in the affinity of a telomerase substrate (single-stranded DNA primer) for the enzyme.
* To whom correspondence should be addressed. Tel: +1 650 473 8631; Fax: +1 650 473 7760; Email: rpruzan{at}geron.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. G. Dikmen, G. C. Gellert, S. Jackson, S. Gryaznov, R. Tressler, P. Dogan, W. E. Wright, and J. W. Shay In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor Cancer Res., September 1, 2005; 65(17): 7866 - 7873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Wang, K. Wu, A. C. Chin, S. Chen-Kiang, K. Pongracz, S. Gryaznov, and M. A. S. Moore Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma Blood, January 1, 2004; 103(1): 258 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patry, L. Bouchard, P. Labrecque, D. Gendron, B. Lemieux, J. Toutant, E. Lapointe, R. Wellinger, and B. Chabot Small Interfering RNA-Mediated Reduction in Heterogeneous Nuclear Ribonucleoparticule A1/A2 Proteins Induces Apoptosis in Human Cancer Cells but not in Normal Mortal Cell Lines Cancer Res., November 15, 2003; 63(22): 7679 - 7688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Akiyama, T. Hideshima, M. A. Shammas, T. Hayashi, M. Hamasaki, Y.-T. Tai, P. Richardson, S. Gryaznov, N. C. Munshi, and K. C. Anderson Effects of Oligonucleotide N3'->P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells Cancer Res., October 1, 2003; 63(19): 6187 - 6194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Asai, Y. Oshima, Y. Yamamoto, T.-a. Uochi, H. Kusaka, S. Akinaga, Y. Yamashita, K. Pongracz, R. Pruzan, E. Wunder, et al. A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent Cancer Res., July 15, 2003; 63(14): 3931 - 3939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Leeper, N. Leulliot, and G. Varani The solution structure of an essential stem-loop of human telomerase RNA Nucleic Acids Res., May 15, 2003; 31(10): 2614 - 2621. [Abstract] [Full Text] [PDF]
|
|